Why the study?
Whether androgen deprivation therapy is associated with an increased risk of developing cardiovascular-related disease was poorly defined.
Does androgen deprivation therapy increase the risk of cardiac events in men with prostate cancer?
Does androgen deprivation therapy increase the risk of cardiac events in men with prostate cancer?
Androgen deprivation therapy in men with prostate cancer is associated with a significantly increased risk of acute myocardial infarction and cardiovascular disease, highlighting the need for baseline cardiovascular evaluation.
ADT may increase cardiac event risk in prostate cancer patients; extends observational evidence but leaves causality and practice change open.
BACKGROUND: Androgen deprivation therapy (ADT) is widely being applied in men who suffered from prostate cancer. Whether androgen deprivation therapy (ADT) is associated with an increased risk of developing cardiovascular-related disease is poorly defined. OBJECTIVES: The aim of the present meta-analysis is to explore the relationship between ADT and the risk of cardiac events. MATERIALS AND METHODS: For this systematic review and meta-analysis, we searched databases from inception to April 2019 for randomized controlled trials (RCT) or observational studies that reported data on ADT administration and cardiac event incidence. The connection was evaluated through estimating relative risk ratio (RR) and 95% confidence intervals (CIs). RESULTS: A significantly increased acute myocardial infarction (AMI) was detected in the ADT group compared with the control group (RR = 1.19, 95% confidence interval (CI), 1.02-1.39, P < .05). A significant difference between cardiovascular disease (CVD) and ADT was also observed, with summary RR = 1.25, 95% CI, 1.11-1.40, P < .05. Furthermore, our study also suggested ADT was not related to increased incidence of sudden cardiac death (SCD) (RR = 1.13, 95% CI, 0.92-1.38, P = .24); AMI and CVD were not connected with the duration of ADT (AMI: RR = 1.31; 95% CI, 0.66-2.63, P = .44, for > 5 year group; CVD: RR = 1.12, 95% CI, 0.97-1.30, P = .12, for > 5 year group). In addition, the RR for risk of CVD was 1.28 (95% CI, 1.01-1.62, P < .05) for men with PCa on new hormonal agents. DISCUSSION: Various ADT modalities have different impact on cardiovascular disease risk in different level. Long-term application of ADT is not associated with increased risk of AMI and CVD. Both abiraterone and enzalutamide could significantly increase the incidence of cardiac events in patients who suffered from prostate cancer. Cautions and periodic cardiovascular elevation are necessary for patients before the ADT starting. CONCLUSIONS: Androgen deprivation therapy is associated with increased risk of AMI, CHD, in contrast, this association is not detected in SCD.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: